Esperion discloses 8.15% stake held by Glazer Capital

Rhea-AI Filing Summary

Esperion Therapeutics reported a Schedule 13G disclosing that Glazer Capital, LLC and Paul J. Glazer hold 20,975,620 shares, representing 8.15% of common stock.

The filing states the shares are held by Glazer-managed funds with shared voting and dispositive power of 20,975,620 shares. The filing lists Glazer Capital Enhanced Master Fund, Ltd. as a holder with the right to receive proceeds. Signatures are dated 06/08/2026.

Insights

Institutional Ownership Analyst

Glazer-managed funds report an 8.15% passive stake in Esperion.

The Schedule 13G shows 20,975,620 shares held by Glazer-managed accounts with shared voting and dispositive power. The filing characterizes the ownership as held on behalf of Glazer-managed funds rather than direct individual ownership.

Key dependencies include any future amendments if ownership or voting arrangements change; subsequent filings would update the percentage or voting control.

Corporate Governance Specialist

The filing attributes voting/dispositive power to Glazer Capital and names a specific Glazer fund as beneficiary.

The statement identifies Glazer Capital Enhanced Master Fund, Ltd. as having the right to receive sale proceeds for a >5% position, and lists the Reporting Persons and their business address. The signature block is dated 06/08/2026.

Stake disclosures like this can affect proxy dynamics; any changes in voting alignment would appear in future ownership amendments.

Key Figures

Shares beneficially owned: 20,975,620 shares Percent of class: 8.15% Signature date: 06/08/2026 +1 more

4 metrics

Shares beneficially owned 20,975,620 shares reported in Item 4 of Schedule 13G

Percent of class 8.15% percent of common stock reported in Item 4

Signature date 06/08/2026 date in signature block

CUSIP 29664W105 security identifier listed in Item 2(d)/(e)

Key Terms

Schedule 13G, Shared Dispositive Power, Beneficially owned, Right to receive proceeds

4 terms

Schedule 13G regulatory

"This statement is filed by: (i) Glazer Capital, LLC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Shared Dispositive Power financial

"Shared Dispositive Power 20,975,620.00"

Beneficially owned regulatory

"Amount beneficially owned: 20,975,620"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Right to receive proceeds financial

"has the right to receive or the power to direct the receipt of the proceeds"

FAQ

What stake does Glazer Capital hold in Esperion (ESPR)?

Glazer Capital and Paul J. Glazer report beneficial ownership of 20,975,620 shares, equal to 8.15% of common stock. The Schedule 13G lists shared voting and dispositive power over those shares and names a Glazer fund as having rights to sale proceeds.

Who is listed as the beneficial holder in the Schedule 13G for ESPR?

The filing is made by Glazer Capital, LLC and Paul J. Glazer as Reporting Persons. It states the shares are held by Glazer-managed funds and identifies Glazer Capital Enhanced Master Fund, Ltd. as a fund with proceeds rights.

What voting and disposition rights are reported by Glazer in the filing?

The Schedule 13G reports 0 sole voting power and 20,975,620 shared voting power, and similarly 0 sole dispositive and 20,975,620 shared dispositive power over the reported shares, per the filing’s Item 4.

Does the filing say Glazer is the beneficial owner under Section 13?

The filing expressly states it should not be construed as an admission that the Reporting Persons are the beneficial owners under Section 13. It identifies Reporting Persons as manager and managed funds rather than asserting legal beneficial ownership.

When was the Esperion Schedule 13G signed and filed?

The signature block shows Paul J. Glazer signed the statement on 06/08/2026. The top of the filing lists an additional date of 06/01/2026 associated with the disclosure header.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 05:10 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Esperion Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

29664W105

(CUSIP Number)

06/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 29664W105

1

Names of Reporting Persons

Glazer Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 20,975,620.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 20,975,620.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

20,975,620.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.15 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 29664W105

1

Names of Reporting Persons

Paul J. Glazer

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 20,975,620.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 20,975,620.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

20,975,620.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.15 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Esperion Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 3891 Ranchero Drive, Suite 150 Ann Arbor, MI 48108
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
(c)	Citizenship: Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 29664W105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 20,975,620
(b)	Percent of class: 8.15%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 20,975,620
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 20,975,620
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2. Glazer Capital Enhanced Master Fund, Ltd., a Glazer Fund, has the right to receive or the power to direct the receipt of the proceeds from the sale of more than 5% of the shares of Common Stock outstanding.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glazer Capital, LLC

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer, Managing Member
Date:	06/08/2026

Paul J. Glazer

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer
Date:	06/08/2026